https://orcid.org/0000-0002-2984-0252
References
- Gotlib J. World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–1259. doi:10.1002/ajh.24880
- Abu-Tineh M, Amer A, Ibrahim F, Ibrahim WH, Alhasson H, Yassin MA. FIP1L1-platelet-derived growth factor receptor A-positive chronic eosinophilic leukemia showing dramatic response to imatinib: a case report. Medicine. 2021;2(1):e0019.
- Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010;95(5):696. doi:10.3324/haematol.2009.021675
- Wang SA. The diagnostic work-up of hypereosinophilia. Pathobiology. 2019;86(1):39–52. doi:10.1159/000489341
- Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR 1: a review. Int J Lab Hematol. 2013;35(5):491–500. doi:10.1111/ijlh.12057
- Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734–742. doi:10.1038/sj.leu.2403313
- Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103(8):2879–2891. doi:10.1182/blood-2003-06-1824
- Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39–44. doi:10.1016/j.jaci.2010.04.011
- Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):415–441. doi:10.1016/j.iac.2007.07.009
- Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714. doi:10.1182/blood-2016-10-695973